- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses
Eloi R. Verrier1,2, Che C. Colpitts1,2, Charlotte Bach1,2, Laura Heydmann1,2, Amélie Weiss3, Mickaël Renaud3, Sarah C. Durand1,2, François Habersetzer4, David Durantel5, Georges Abou-Jaoudé6, Maria M. López Ledesma7, Daniel J. Felmlee1,2, Magali Soumillon8, Tom Croonenborghs9,10, Nathalie Pochet9, Michael Nassal11, Catherine Schuster1,2, Laurent Brino3, Camille Sureau6,*, Mirjam B. Zeisel1,2 andThomas F. Baumert1,2,4,*
Article first published online: 6 OCT 2015
DOI: 10.1002/hep.28013
© 2015 by the American Association for the Study of Liver Diseases
Issue
Hepatology
Hepatology
Volume 63, Issue 1, pages 35–48, January 2016
Article has an altmetric score of 4
Additional Information(Show All)
How to Cite
Author Information
Publication History
Author Information
1 Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
2 Université de Strasbourg, Strasbourg, France
3 IGBMC, Plateforme de Criblage Haut-débit, Illkirch, France
4 Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Nouvel Hôpital Civil, Strasbourg, France
5 Inserm, U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Université de Lyon, Lyon, France
6 INTS, Laboratoire de Virologie Moléculaire, Paris, France
7 Cátedra de Virología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina
8 Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA
9 Program in Translational NeuroPsychiatric Genomics, Brigham and Women's Hospital, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA
10 KU Leuven Technology Campus Geel, AdvISe, Geel, Belgium
11 Department of Internal Medicine II/Molecular Biology, University Hospital Freiburg, Freiburg, Germany
*Address reprint requests to: Thomas F. Baumert, M.D., Inserm U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 3 Rue Koeberlé, 67000 Strasbourg, France. E-mail: [email protected]; tel: +33 3 68 85 37 03; fax: +33 3 68 85 37 24. Or: Camille Sureau, Ph.D., Laboratoire de Virologie Moléculaire, Institut National de la Transfusion Sanguine, 6 rue Alexandre-Cabanel, 75739 Paris, France. E-mail: [email protected]; fax: +33 1 44 49 30 56.
Potential conflict of interest: Nothing to report.
Supported by Inserm, University of Strasbourg, the European Union (EU-INTERREG-IV-Rhin Supérieur-FEDER Hepato-Regio-Net 2012; ERC-2008-AdG-233130-HEPCENT; FP7 305600 HepaMab; EU Infect-Era hepBccc), ANRS (2012/318, 2013/108), and the French Cancer Agency (ARC IHU201301187). This work has been published under the framework of the LABEX ANR-10-LAB-28 and benefits from funding from the state managed by the French National Research Agency as part of the Investments for the future program. Also supported by a fellowship from the Canadian Institutes of Health Research (201411MFE-338606-245517, to C.C.C.).
Chronic hepatitis B and D infections are major causes of liver disease and hepatocellular carcinoma worldwide. Efficient therapeutic approaches for cure are absent. Sharing the same envelope proteins, hepatitis B virus and hepatitis delta virus use the sodium/taurocholate cotransporting polypeptide (a bile acid transporter) as a receptor to enter hepatocytes. However, the detailed mechanisms of the viral entry process are still poorly understood. Here, we established a high-throughput infectious cell culture model enabling functional genomics of hepatitis delta virus entry and infection. Using a targeted RNA interference entry screen, we identified glypican 5 as a common host cell entry factor for hepatitis B and delta viruses. Conclusion: These findings advance our understanding of virus cell entry and open new avenues for curative therapies. As glypicans have been shown to play a role in the control of cell division and growth regulation, virus–glypican 5 interactions may also play a role in the pathogenesis of virus-induced liver disease and cancer. (Hepatology 2016;63:35–48)
|
|